Immunology and Dermatology
Research in atopic dermatitis focuses on treatment response prediction, with interest in cyclosporin optimisation and the use of genetic, kinetic, and immunological markers to guide therapy.
- Biomarker-driven treatment selection
- Pharmacokinetic and pharmacodynamic modelling
- Multi-omic response prediction
The sponsor also supports personalised approaches in immune-mediated disease management, linking laboratory markers with clinical decision-making.
Psychiatry and Pharmacogenetics
In depressive disorder, the sponsor funds work on pre-emptive pharmacogenetic testing to support antidepressant selection after prior treatment failure, with attention to clinical and medication-related factors.
- Antidepressant response prediction
- Precision psychiatry
- Genetic-guided therapy selection
This area reflects a strong interest in tailoring mental health treatment to individual biological and clinical profiles.
HIV, Cardiovascular disease, and Metabolic aging
Trials in HIV infection address both long-term comorbidity management and cardiovascular risk, including coronary artery inflammation, high cardiovascular risk, and age-related biological change.
- Cardiovascular risk reduction in people living with HIV
- Inflammation-focused therapy
- Epigenetic age acceleration
Additional work includes statin safety and pharmacogenomic strategies for patients at risk of treatment-related muscle toxicity.
Transplantation, Infectious diseases, and Antimicrobial therapy
The sponsor supports research in kidney transplant care through optimisation of tacrolimus exposure, alongside studies in pulmonary tuberculosis, bacterial pneumonia, and resistant intestinal giardiasis.
- Immunosuppressant optimisation
- Tuberculosis biomarker development
- Antiparasitic and antibacterial treatment evaluation
These activities show a clear emphasis on infectious disease diagnostics and therapy across both chronic and acute settings.
Neurology, Regenerative medicine, and Paediatric haematology-oncology
Clinical research also includes ischemic stroke with interest in mesenchymal stem cells, and refractory/relapsed acute lymphoblastic leukemia in children, adolescents, and young adults through CAR-T cell therapy.
- Cell-based therapy in stroke
- Immunotherapy for relapsed leukemia
- Paediatric and young adult oncology
These studies extend the sponsor’s portfolio into advanced therapy development for neurological injury and difficult-to-treat blood cancers.
